NCAPH and nonpapillary renal cell carcinoma: Additionally, NCAPH’s promotion of ccRCC growth and resistance to anti-PD-1 therapy underscores its potential as a prognostic predictor and immunomodulatory target, as well as an effective therapeutic strategy for this malignancy (Figures 1, 2; Table 1).